Experienced in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Dr. Nancy J. Bunin

Pediatric Hematology Oncology
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/onc, 
Philadelphia, PA 
Clinical Trials:Currently Recruiting for 5 Trials
Experienced in Paroxysmal Nocturnal Hemoglobinuria (PNH)
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/onc, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nancy Bunin is a Pediatric Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Bunin is rated as an Experienced provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Her top areas of expertise are Severe Combined Immunodeficiency (SCID), Graft Versus Host Disease (GvHD), Hepatic Venoocclusive Disease with Immunodeficiency, X-Linked Severe Combined Immunodeficiency, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 66 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 1 clinical trial in the study of Paroxysmal Nocturnal Hemoglobinuria (PNH).

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in PA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/onc, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Bunin has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Enrollment Status: Recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Device
Study Drug: Busulfan
Study Phase: Phase 2
A Pilot Study in the Treatment of BK Virus Infection With Cytotoxic T Cells in Immunocompromised Transplant Patients
A Pilot Study in the Treatment of BK Virus Infection With Cytotoxic T Cells in Immunocompromised Transplant Patients
Enrollment Status: Recruiting
Publish Date: April 29, 2025
Intervention Type: Biological
Study Phase: Early Phase 1
CD45RA Depleted Peripheral Stem Cell Addback for Patients At Risk for Viral or Fungal Infections Post TCRαβ/CD19 Depleted Hematopoietic Stem Cell Transplant
CD45RA Depleted Peripheral Stem Cell Addback for Patients At Risk for Viral or Fungal Infections Post TCRαβ/CD19 Depleted Hematopoietic Stem Cell Transplant
Enrollment Status: Recruiting
Publish Date: March 05, 2025
Intervention Type: Device
Study Phase: Not Applicable
Expanded Access Protocol Using CD3+/CD19+ Depleted Unrelated Donor or Related Donor Peripheral Stem Cells
Expanded Access Protocol Using CD3+/CD19+ Depleted Unrelated Donor or Related Donor Peripheral Stem Cells
Enrollment Status: Recruiting
Publish Date: February 05, 2025
Intervention Type: Device
Study Phase: Early Phase 1
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 19, 2024
Intervention Type: Biological
Study Phase: Phase 2
Unrelated And Partially Matched Related Donor Peripheral Blood Stem Cell Transplantation (PSCT) With TCR αβ + T Cell And B Cell Depletion For Patients With Acquired And Inherited Bone Marrow Failure
Unrelated And Partially Matched Related Donor Peripheral Blood Stem Cell Transplantation (PSCT) With TCR αβ + T Cell And B Cell Depletion For Patients With Acquired And Inherited Bone Marrow Failure
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Device
Study Phase: Not Applicable
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2025
Intervention Type: Biological
Study Drug: Virus Specific T-cell infusion
Study Phase: Phase 1/Phase 2
UNRELATED AND PARTIALLY MATCHED RELATED DONOR PERIPHERAL STEM CELL TRANSPLANTATION WITH Alpha/Beta T CELL AND B CELL DEPLETION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES
UNRELATED AND PARTIALLY MATCHED RELATED DONOR PERIPHERAL STEM CELL TRANSPLANTATION WITH Alpha/Beta T CELL AND B CELL DEPLETION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES
Enrollment Status: Active_not_recruiting
Publish Date: January 01, 2025
Intervention Type: Device
Study Phase: Phase 2
Phase II Study for Patients With Primary Immunodeficiencies Using and Cd19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells
Phase II Study for Patients With Primary Immunodeficiencies Using and Cd19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells
Enrollment Status: Active_not_recruiting
Publish Date: January 01, 2025
Intervention Type: Device
Study Phase: Phase 2
Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders
Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2024
Intervention Type: Drug
Study Phase: Phase 2
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Enrollment Status: Terminated
Publish Date: January 25, 2021
Intervention Type: Other, Drug
Study Phase: Phase 2
A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy
A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy
Enrollment Status: Terminated
Publish Date: May 21, 2020
Intervention Type: Genetic
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
View 9 Less Clinical Trials

66 Total Publications

Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Monogenic Inflammatory Bowel Disease.
Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Monogenic Inflammatory Bowel Disease.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: January 30, 2025
Similar Doctors
Advanced in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Dr. Timothy S. Olson
Pediatric Hematology Oncology
Advanced in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Dr. Timothy S. Olson
Pediatric Hematology Oncology
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/onc, 
Philadelphia, PA 
 (0.1 miles away)
215-590-3535
Languages Spoken:
English
See accepted insurances

Timothy Olson is a Pediatric Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Olson is rated as a Distinguished provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). His top areas of expertise are Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Anemia, Bone Marrow Transplant, and Splenectomy.

Advanced in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Dr. Peter Kurre
Pediatric Hematology Oncology
Advanced in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Dr. Peter Kurre
Pediatric Hematology Oncology
3401 Civic Center Blvd, 
Philadelphia, PA 
 (0.1 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Peter Kurre is a Pediatric Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Kurre is rated as a Distinguished provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). His top areas of expertise are Fanconi Anemia, Congenital Aplastic Anemia, Aplastic Anemia, Anemia, and Bone Marrow Transplant.

Experienced in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Dr. Michele Lambert
Pediatric Hematology Oncology
Experienced in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Dr. Michele Lambert
Pediatric Hematology Oncology

Childrens Health Care Associates Inc

3401 Civic Ctr Blvd, 
Philadelphia, PA 
 (0.1 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Michele Lambert is a Pediatric Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Lambert is rated as a Distinguished provider by MediFind in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Her top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Blood Clots, Evans Syndrome, Multisystem Inflammatory Syndrome in Children (MIS-C), and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bunin's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile